Search

Your search keyword '"Minghui Cao"' showing total 3 results
Start Over Author "Minghui Cao" Topic antineoplastic agents Publication Year Range Last 10 years
3 results on '"Minghui Cao"'

1. Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model

Author

Qinyuan Zhang, Liejing Lu, Zhe Wang, Zehong Yang, Jiaji Mao, Minghui Cao, Jun Shen, Jingzhong Zhang, Fang Zhang, Xiang Zhang, Xiaohui Duan, and Wangshu Zhu

Subjects
0301 basic medicine, Male, Cancer Research, medicine.medical_treatment, CD8-Positive T-Lymphocytes, Random Allocation, 0302 clinical medicine, Genes, Reporter, Immunology and Allergy, Medicine, RC254-282, Clinical/Translational Cancer Immunotherapy, neurooncology, Brain Neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Glioma, Magnetic Resonance Imaging, Up-Regulation, molecular immunogene, Real-time polymerase chain reaction, Oncology, 030220 oncology & carcinogenesis, Systemic administration, Molecular Medicine, MRI, Immunology, Antineoplastic Agents, Mesenchymal Stem Cell Transplantation, Viral vector, 03 medical and health sciences, In vivo, image analysis, Animals, Pharmacology, business.industry, Mesenchymal stem cell, Lentivirus, Mesenchymal Stem Cells, Immunotherapy, Dendritic Cells, Interferon-beta, medicine.disease, Xenograft Model Antitumor Assays, Rats, Inbred F344, Rats, 030104 developmental biology, Apoferritins, Cancer research, business, CD8
Abstract

BackgroundImmunotherapy with IFNβ is a promising strategy for treating malignant glioma. However, systemic administration of IFNβ is inadequate because of low intratumoral concentration and major adverse effects. This study aimed to determine whether mesenchymal stem cells (MSCs) can be used as cellular vehicles to locally deliver IFNβ for glioma therapy by using in vivo MRI tracking.MethodsA recombinant lentiviral vector encoding IFNβ and ferritin heavy chain (FTH) reporter genes was constructed to transduce MSCs. The effectiveness and safety of transduction were assessed. After the IFNβ and FTH overexpressed MSCs (IFNβ-FTH-MSCs) were transplanted into intracranial orthotopic rat F98 gliomas via peritumoral, intracerebral, intratumoral or intra-arterial injection, MRI was performed to track IFNβ-FTH-MSCs and to evaluate their therapeutic effect on glioma in vivo, as validated by histologic analysis, quantitative PCR and ELISA assays.ResultsMSCs were efficiently and safely transduced to upregulate their IFNβ secretion and FTH expression by the constructed lentivirus. After peritumoral injection, IFNβ-FTH-MSCs appeared as hypointense signals on MRI, which gradually diminished but remained visible until 11 days. Compared with other administration routes, only peritumoral injection of IFNβ-FTH-MSCs showed a remarkable inhibition on the glioma growth. Nearly 30% of IFNβ-FTH-MSCs survived up to 11 days after peritumoral injection, while most of IFNβ-FTH-MSCs injected via other routes died within 11 days. IFNβ-FTH-MSCs grafted peritumorally secreted IFNβ persistently, leading to pronounced Batf3+dendritic cells and CD8+T lymphocyte infiltration within the glioma.ConclusionsMSCs can be used as cellular vehicles of IFNβ to treat malignant glioma effectively via peritumoral injection.

Published
2020

2. A polyprodrug-based nanoplatform for cisplatin prodrug delivery and combination cancer therapy

Author

Xiao-Ding Xu, Yiran Tao, Hai Huang, Chunhao Lin, Minghui Cao, and Phei Er Saw

Subjects
Polymers, Antineoplastic Agents, 010402 general chemistry, 01 natural sciences, Catalysis, Drug Delivery Systems, Combination cancer therapy, Cell Line, Tumor, Materials Chemistry, medicine, Combined Modality Therapy, Humans, Prodrugs, Particle Size, Cell Proliferation, Cisplatin, Mitoxantrone, 010405 organic chemistry, business.industry, Optical Imaging, Metals and Alloys, General Chemistry, Neoplasms, Experimental, Prodrug, Small molecule, 0104 chemical sciences, Surfaces, Coatings and Films, Electronic, Optical and Magnetic Materials, Cell culture, Ceramics and Composites, Cancer research, Experimental pathology, Nanoparticles, Drug Screening Assays, Antitumor, business, Reactive Oxygen Species, medicine.drug
Abstract

Polyprodrug-based delivery technique is a fast-growing and effective strategy to improve the therapeutic efficacy of small molecule drugs. We herein developed a robust mitoxantrone (MTO)-based polyprodrug nanoplatform for systemic cisplatin prodrug delivery and combination cancer therapy. Our results show that this nanoplatform can concurrently transport MTO and cisplatin to tumor cells and significantly inhibit tumor growth.

Published
2019

3. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.

Author

Wei Wu, Heran Deng, Nanyan Rao, Na You, Yaping Yang, Minghui Cao, Jieqiong Liu, Wu, Wei, Deng, Heran, Rao, Nanyan, You, Na, Yang, Yaping, Cao, Minghui, and Liu, Jieqiong

Subjects
ADJUVANT treatment of cancer, EVEROLIMUS, BREAST cancer treatment, LETROZOLE, FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE, PROTEIN analysis, ANTHROPOMETRY, ANTINEOPLASTIC agents, BREAST tumors, CELL receptors, COMBINED modality therapy, COMPARATIVE studies, EXPERIMENTAL design, HETEROCYCLIC compounds, RESEARCH methodology, MEDICAL cooperation, RESEARCH protocols, METASTASIS, ORGANIC compounds, RESEARCH, STATISTICAL sampling, PILOT projects, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, POSTMENOPAUSE
Abstract

Background: The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as compared with ER-negative, HER2-positive or triple-negative tumors. Neoadjuvant endocrine therapy (NET) is an attractive alternative to NAC for ER-positive, HER2-negative cancer. However, a prior trial comparing NET with standard NAC in ER-positive tumor showed that the difference of response was not significant. Studies demonstrated that the mTOR inhibitor everolimus could sensitize breast tumors to endocrine therapy. A pilot open-label, randomized trial has been designed to evaluate the feasibility, efficacy and tolerability of neoadjuvant everolimus plus letrozole versus NAC in treating postmenopausal women with ER-positive, HER2-negative breast cancer.Methods: Forty postmenopausal women with non-metastatic ER-positive, HER2-negative invasive breast cancer with a primary tumor > 2 cm or positive axillary lymph node(s) proved by biopsy will be randomly (1:1) enrolled from Sun Yat-Sen Memorial Hospital to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles before surgery. Primary outcome is the feasibility of the trial. Secondary outcome measures include ultrasound response rate, pathological complete response rate, breast-conserving surgery rate, toxicities, and changes in the percentages of peripheral blood CD4+ T cells, CD8+ T cells, T helper cells, regulatory T cells, and NK cells.Discussion: This is the first study to determine the feasibility, efficacy and tolerability of head-to-head neoadjuvant everolimus plus letrozole versus neoadjuvant FEC in treating postmenopausal women with ER-positive, HER2-negative breast cancer. The trial will provide evidence to assess the feasibility of a future multicenter, randomized controlled trial, and will provide valuable clinical data of the immunoregulatory effect of everolimus in breast cancer.Trial Registration: ClinicalTrials.gov registry, ID: NCT02742051 . Registered on 7 April 2016. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results